It would not be a surprise if the Positron Corp (OTC: POSC) stock is one of those in sharp focus among investors. On Tuesday the company had been in the news after it made a significant new announcement about the sales of two of its noted products. In this feature, we will take a closer look at the developments.
New Sales
In the news release yesterday, the company announced that it had closed the sales of its Attrius PET and NeuSight PET-CT 64 slice nuclear imaging systems to a noted cardiology specialist entity. Thanks to the new purchases, the cardiology specialist would be able to assess and treat cardiovascular diseases. Positron Corp went on to stated that the advanced technologies had been developed with aim of providing unparalleled diagnostic precision and value for money to molecular imagery and nuclear cardiology services. In light of the announcement, the Positron Corp could well be the one worth tracking today.
Further Information
The company stated in the news release that there was significant excitement at the fact that noted physicians in the particular field had recognized the advantages of using its services. It was further noted that the recent sales were an indication of its growing clout in the market.
Management Quote
Adel Abdullah, President of Positron stated, “We are pleased that esteemed physicians in the nuclear cardiovascular field recognize the advantages of our systems and services. These recent sales are very positive indicators of our growing momentum in the marketplace. We believe our technology, comprehensive support, and unmatched value uniquely position us to advance the adoption of PET imaging and cardiovascular care.” Mr. Abdullah added, “We are thrilled to work with such a distinguished physician dedicated to providing expert care. We look forward to supporting their growth and ensuring they fully utilize the capabilities of our Attrius PET and NeuSight PET-CT systems in delivering outstanding outcomes for their patients.”
